

**Preliminary program**

**08.00 – 08.30: Breakfast and registration**

**08.30 – 08.50: Welcome and introduction**

*Andrew Kay, Chief Executive Officer*

**08.50 – 10.05: Prostate cancer: The importance of bone metastases and the future role of Alpha Pharmaceuticals**

*Sten Nilsson, Head of the Urologic Oncology Group at the Karolinska Hospital and Institute in Stockholm and Principal Investigator of Algeta's phase II clinical trial with Alpharadin*

**10.05 – 10.15: Coffee break**

**10.15 – 10.30: Production of Alpharadin**

*Kari Dyvik, VP operations*

**10.30 – 10.50: Potential to develop the alpha-pharmaceutical pipeline with thorium targeted alpha-therapy**

*Thomas Ramdahl, Executive Vice President & Chief Technology Officer*

**10.50 – 11.00: Closing comments**

*Andrew Kay, Chief Executive Officer*

**11.00 – 11.30: Lunch**